Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 751 shares, a decrease of 84.8% from the June 15th total of 4,938 shares. Based on an average daily volume of 13,699 shares, the days-to-cover ratio is presently 0.1 days.
Fortress Biotech Trading Down 1.3%
FBIOP stock traded down $0.24 during midday trading on Friday, reaching $18.56. 8,330 shares of the company’s stock traded hands, compared to its average volume of 23,866. The company has a 50-day moving average price of $18.37 and a two-hundred day moving average price of $14.51. Fortress Biotech has a 52 week low of $6.27 and a 52 week high of $21.43.
About Fortress Biotech
Fortress Biotech, Inc (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.
The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy.
Featured Stories
- Five stocks we like better than Fortress Biotech
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
